Actinium Pharmaceuticals (ATNM) EBIT (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly EBIT of -$5.9 million for Q1 2026, up 64.52% year-over-year from -$3.6 million in Q1 2025, and up 7.97% quarter-over-quarter from -$6.4 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) EBIT (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported EBIT for 17 consecutive years, with -$5.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT rose 64.52% year-over-year to -$5.9 million; the TTM figure through Mar 2026 stood at -$25.5 million (up 48.11% YoY), while the FY2025 annual figure was -$36.2 million, up 13.95% from the prior year.
- EBIT climbed to -$5.9 million in Q1 2026 per ATNM's latest filing, from -$6.4 million in the prior quarter.
- Across five years, EBIT topped out at -$5.2 million in Q1 2022 and bottomed at -$16.6 million in Q1 2025.
- Historically, EBIT has averaged -$10.0 million across 5 years, with a median of -$9.8 million in 2022.
- Annual changes were most pronounced in 2023 — EBIT plunged 124.32% — and 2026, when it surged 64.52%.
- Actinium Pharmaceuticals' EBIT stood at -$11.3 million in 2022, then climbed by 8.4% to -$10.3 million in 2023, then increased by 27.44% to -$7.5 million in 2024, then increased by 14.54% to -$6.4 million in 2025, then gained by 7.97% to -$5.9 million in 2026.
- Business Quant data shows ATNM's EBIT at -$5.9 million in Q1 2026, -$6.4 million in Q4 2025, and -$5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Actinium Pharmaceuticals | 34.85 Mn | 34.85 Mn | - | 27.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.57 Mn |
| Mar 31, 2026 | -5.90 Mn |
| Dec 31, 2025 | -6.41 Mn |
| Sep 30, 2025 | -5.69 Mn |
| Jun 30, 2025 | -7.50 Mn |
| Mar 31, 2025 | -16.64 Mn |
| Dec 31, 2024 | -7.51 Mn |
| Sep 30, 2024 | -12.60 Mn |
| Jun 30, 2024 | -12.42 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Dec 31, 2023 | -10.34 Mn |
| Sep 30, 2023 | -14.35 Mn |
| Jun 30, 2023 | -15.64 Mn |
| Mar 31, 2023 | -11.58 Mn |
| Dec 31, 2022 | -11.29 Mn |
| Sep 30, 2022 | -9.80 Mn |
| Jun 30, 2022 | -7.85 Mn |
| Mar 31, 2022 | -5.16 Mn |
| Dec 31, 2021 | -8.05 Mn |
| Sep 30, 2021 | -6.47 Mn |